Neoadjuvant nab-paclitaxel in breast cancer: who stands to benefit?

Laura Biganzoli, Amelia McCartney


In the treatment of early breast cancer, the addition of a sequential taxane following an anthracycline-based regimen has improved patient outcomes (1), with studies suggesting that weekly solvent-based paclitaxel given after an anthracycline regimen significantly reduces the risk of relapse (2,3).

Article Options

Download Citation